文献速递妇科

晚期卵巢癌中心膈淋巴结增大的临床意义:对生存的影响

Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
PubMed 文献 · Gynecol Oncol · 2017-11-10

研究纳入253例接受初次减瘤术的IIIC/IV期卵巢癌患者,用三种定义评估术前CT中心膈淋巴结异常。QAS定义下28例(11.1%)异常。无肉眼残留患者中异常CPLN与较差OS相关(中位OS 38.4 vs 69.6个月,p=0.08);有残留者无关联。存在异常CPLN时,NGR与RD的OS无差异(38.4 vs 37.5个月,p=0.99)。

要点

  • QAS定义下11.1%(28/253)患者中心膈淋巴结异常,仅1例手术切除。
  • 无肉眼残留者中,异常CPLN与较差OS相关但未达统计学显著(38.4 vs 69.6个月,p=0.08)。
  • 存在异常CPLN时,NGR与RD的OS无差异(38.4 vs 37.5个月,p=0.99)。

核心结论

  • 异常中心膈淋巴结是晚期卵巢癌生存的重要预测因素。
  • 当治疗目标为无肉眼残留时,应考虑对异常中心膈淋巴结进行管理。

研究设计与样本

  • 纳入接受初次减瘤术的IIIC/IV期卵巢癌患者,要求残留病灶≤1.0cm且术前有腹盆腔CT。
  • 共253例患者,平均年龄64.0岁;136例无肉眼残留,117例有残留病灶。
  • CT由两名盲法放射科医生审阅,用三种定义评估中心膈淋巴结异常:定性评估评分(QAS)、短轴>7mm、短轴≥10mm。
  • 采用log-rank检验比较总生存(OS)。

主要发现

  • QAS定义下,28例(11.1%)患者中心膈淋巴结异常,其中1例被切除。
  • 无肉眼残留患者中,异常CPLN与较差OS相关(中位OS 38.4 vs 69.6个月,p=0.08)。
  • 有残留病灶患者中,异常CPLN与OS无关联(中位OS 37.5 vs 28.5个月,p=0.49)。
  • 无异常CPLN时,无肉眼残留组OS显著优于有残留组(中位OS 69.6 vs 28.5个月,p<0.001)。
  • 存在异常CPLN时,无肉眼残留组与有残留组OS无差异(中位OS 38.4 vs 37.5个月,p=0.99)。

临床怎么用

  • 作者认为,异常中心膈淋巴结是晚期卵巢癌生存的重要预测因素。
  • 作者认为,当治疗目标为无肉眼残留时,应考虑对异常中心膈淋巴结进行管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Advanced ovarian cancer (OC) commonly spreads to cardiophrenic lymph nodes (CPLNs), and is often visible on preoperative imaging. We investigated the prognostic significance of abnormal CPLNs in OC detected by preoperative CT scans using three different definitions. METHODS: Patients undergoing primary debulking surgery for stage IIIC/IV with residual disease (RD) ≤1.0cm and a preoperative abdominopelvic CT scan available were included. Scans were reviewed by two blinded radiologists. We characterized abnormal CPLNs using three different definitions: i) qualitative assessment score (QAS); ii) nodes >7mm on the short axis; or, iii) nodes ≥10mm on the short axis. We compared overall survival (OS) using the log-rank test. RESULTS: Of the 253 patients (mean age 64.0years), 136 had no gross residual disease (NGR) and 117 had RD. By the QAS definition, CPLNs were abnormal in 28 (11.1%) patients and removed in one case. Among patients with NGR, presence of abnormal CPLNs was associated with worse OS (median OS, 38.4 vs. 69.6months, p=0.08). We observed no association between abnormal CPLNs and OS among patients with RD (median OS, 37.5 vs. 28.5months, p=0.49). OS was significantly better in NGR group without abnormal CPLNs (median OS for NGR vs. RD, 69.6 vs. 28.5months, p<0.001); however, there was no difference in OS between patients with NGR versus RD when abnormal CPLNs were present (median OS, 38.4 vs. 37.5months, p=0.99). Lack of benefit from NGR when abnormal CPLNs were present was observed for all three definitions tested. CONCLUSION: Abnormal CPLNs are an important predictor of survival in advanced stage OC. Management of abnormal CPLNs should be considered in treatment planning when the goal is NGR.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mert I, Kumar A, Sheedy SP, et al. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival. Gynecol Oncol. 2017. PMID: 29129390. doi:10.1016/j.ygyno.2017.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。